Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck and Idera form vaccine pact
December 18, 2006
| A version of this story appeared in
Volume 84, Issue 51
Merck has licensed Idera Pharmaceuticals' toll-like receptor (TLR) agonists for use in vaccines it is developing for oncology, infectious diseases, and Alzheimer's disease. Merck will make an initial licensing payment of $20 million and has agreed to buy $10 million of Idera stock. Idera could receive up to $165 million in milestones if vaccines across all three therapeutic indications reach the market. Merck will combine its therapeutic and prophylactic vaccines with Idera compounds targeting TLRs 7, 8, and 9, which help mediate human immune response.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter